Table 2. Baseline characteristics of 39 CTC-positive CRPC patients.
| Baseline Characteristics | CTC-Positive Patients (N = 39) | PSMA Negative (N = 19) | PSMA Positive (N = 20) | P |
|---|---|---|---|---|
| Age (years) median (range) | 73 (51–89) | 71 (51–88) | 75 (54–89) | 0.045 |
| Gleason sum at diagnosis median (6-8/9-10) N (%) | 6–8:29 (74.4%) / 9–10:8 (22.2%) |
6–8:14 (73.7%) / 9–10:5 (26.3%) |
6–8:15 (75.0%) / 9–10:3 (15.0%) |
0.692 |
| Tumor stage at diagnosis (T1-3/T4) N (%) | T1-3: 23 (59.0%) / T4:11 (28.2%) |
T1-3:11 (57.9%) / T4:6 (31.6%) | T1-3:12 (60.0%) / T4:5 (25.0%) | >0.999 |
|
Time since diagnosis (y) median (range) |
2.0 (0.50–15.0) | 1.5 (0.50–8.6) | 4.0 (0.50–15.0) | 0.112 |
| Presence of visceral meta (y/n) N (%) | Yes 11 (28.2%) / No 28 (71.8%) |
Yes 6 (31.6%) / No 13 (68.4%) |
Yes 5 (25.0%) / No 15 (75.0%) |
0.731 |
| Presence of bone meta (y/n) N (%) | Yes 30 (76.9%) / No 9 (23.1%) |
Yes 14 (73.7%) / No 5 (26.3%) |
Yes 16 (80.0%) / No 4 (20.0%) |
0.716 |
| Presence of lymph node meta (y/n) N (%) | Yes 18 (46.2%) / No 21 (53.8%) |
Yes 7 (36.8%) / No 12 (63.2%) |
Yes 11 (55.0%) / No 9 (45.0%) |
0.340 |
|
Baseline BSI median (%) (range) |
0.80 (0–9.86) | 0.89 (0–6.48) | 0.6 (0–9.86) | 0.364 |
| Presence of AR-V7 in CTC (y/n) N (%) | Yes 6 (15.4%) / No 33 (84.6%) | Yes 1 (5.3%) / No 18 (94.7%) | Yes 5 (25.0%) / No 15 (75.0%) |
0.181 |
| Baseline LDH median (U/L) (range) | 208 (136–840) | 221 (136–432) | 205 (151–840) | 0.910 |
|
Baseline ALP median (U/L) (range) |
287 (112–1114) | 351 (112–999) | 280 (115–1114) | >0.999 |
| Baseline PSA median (ng/ml) (range) | 40.4 (0.92–799) | 23.5 (0.92–578) | 112 (4.16–799) | 0.023 |
| Treatment lines for CRPC (Pre-1st/2nd-4th) | Pre-1st:32 (82.1%) / 2nd-4th:7 (17.9%) | Pre1st:18 (94.7%) / 2nd-4th:1 (5.3%) | Pre1st:14 (70.0%) / 2nd-4th:6 (30.0%) | 0.091 |
| Prior use of ENZ (y/n) N (%) | Yes 10 (25.6%) / No 29 (74.4%) |
Yes 1 (5.3%) / No 18 (94.7%) | Yes 9 (45.0%) / No 11 (55.0%) |
0.008 |
| Prior use of ABI (y/n) N (%) | Yes 10 (29.6%) / No 29 (70.4%) |
Yes 3 (15.8%) / No 16 (84.2%) |
Yes 7 (35.0%) / No 13 (65.0%) |
0.273 |
| Prior use of DOC (y/n) N (%) | Yes 9 (23.1%) / No 30 (76.9%) | Yes 5 (26.3%) / No 14 (73.7%) |
Yes 4 (20.0%) / No 16 (80.0%) |
0.716 |
| Prior use of CBZ (y/n) N (%) | Yes 0 (0%) / No 39 (100%) | Yes 0 (0%) / No 19 (100%) | Yes 0 (%) / No 20 (100%) | - |
| Type of local treatment N (%) (surgery) | Yes 3 (7.7%) / No 36 (92.3%) | Yes 2 (10.5%) / No 17 (89.5%) |
Yes 1 (5.0%) / No 19 (95.0%) | 0.605 |
| Type of local treatment N (%) (radiation) | Yes 3 (7.7%) / No 36 (92.3%) | Yes 1 (5.3%) / No 18 (94.7%) | Yes 2 (10.0%) / No 18 (90.0%) |
>0.999 |
The baseline characteristics of 39 CTC-positive patients before treatment change were indicated in the “CTC-Positive Patients” column. They were subsequently classified according to PSMA status, and the same variables were used to compare the PSMA-positive and negative cohorts. Fisher’s exact test was used for categorical variables, and Wilcoxon Mann-Whitney test was used for continuous variables.